Evidence map›Paper›PMID 36494494›Full record

ReviewNature protocols2023

High-quality and robust protein quantification in large clinical/pharmaceutical cohorts with IonStar proteomics investigation.

Shichen Shen, Xue Wang, Xiaoyu Zhu, Sailee Rasam, Min Ma, Shihan Huo, Shuo Qian, Ming Zhang, Miao Qu, Chenqi Hu and 7 more

Open access · greenAbstract readReview
In one paragraph

Review in Nature protocols, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
2.2field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 24 citations in OpenAlex.

  1. Article
  2. Proceedings of the National Academy of Sciences of the United States of America · 2026
    Article
  3. L-Fucose-Dependent Biofilm Formation bybioRxiv : the preprint server for biology · 2026
    Article
  4. bioRxiv : the preprint server for biology · 2026
    Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Therapeutic TNF Inhibitors Exhibit Differential Levels of Efficacy in Accelerating Cutaneous Wound Healing.JID innovations : skin science from molecules to population health · 2024
    Article
  15. Article
  16. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 5 institutions in 2 countries.

Shichen Shen *Department of Pharmaceutical Sciences, School of Pharmacy and Pharmaceutical Sciences, University at Buffalo, Buffalo, NY, USA.
Xue Wang *Department of Pharmaceutical Sciences, School of Pharmacy and Pharmaceutical Sciences, University at Buffalo, Buffalo, NY, USA.
Xiaoyu ZhuDepartment of Pharmaceutical Sciences, School of Pharmacy and Pharmaceutical Sciences, University at Buffalo, Buffalo, NY, USA.
Sailee RasamDepartment of Biochemistry, Jacobs School of Medicine and Biomedical Sciences, University at Buffalo, Buffalo, NY, USA.
Min MaDepartment of Cell Stress Biology, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA.ORCID http://orcid.org/0000-0002-4203-5215
Shihan HuoDepartment of Pharmaceutical Sciences, School of Pharmacy and Pharmaceutical Sciences, University at Buffalo, Buffalo, NY, USA.
Shuo QianDepartment of Cell Stress Biology, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA.ORCID http://orcid.org/0000-0002-9038-9704
Ming ZhangDepartment of Pharmaceutical Sciences, School of Pharmacy and Pharmaceutical Sciences, University at Buffalo, Buffalo, NY, USA.
Miao QuDepartment of Neurology, Xuanwu Hospital, Beijing, China.
Chenqi HuAbbVie Bioresearch Center, Worcester, MA, USA.
Liang JinAbbVie Bioresearch Center, Worcester, MA, USA.ORCID http://orcid.org/0000-0002-8659-0536
Yu TianAbbVie Bioresearch Center, Worcester, MA, USA.
Sanjay SethiDepartment of Medicine, Jacobs School of Medicine and Biomedical Sciences, University at Buffalo, Buffalo, NY, USA.ORCID http://orcid.org/0000-0003-0809-7604
David PoulsenDepartment of Neurosurgery, Jacobs School of Medicine and Biomedical Sciences, University at Buffalo, Buffalo, NY, USA.ORCID http://orcid.org/0000-0002-7793-2813
Jianmin WangDepartment of Biostatistics and Bioinformatics, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA.ORCID http://orcid.org/0000-0001-7527-0409
Chengjian TuBioProduction Group, Thermo Fisher Scientific, Buffalo, NY, USA.
Jun QuDepartment of Pharmaceutical Sciences, School of Pharmacy and Pharmaceutical Sciences, University at Buffalo, Buffalo, NY, USA. junqu@buffalo.edu.ORCID http://orcid.org/0000-0002-1346-6809
University at Buffalo, State University of New York · USAbbVie (United States) · USRoswell Park Comprehensive Cancer Center · USBeijing Xuanwu Traditional Chinese Medicine Hospital · CNThermo Fisher Scientific (United States) · US

Funding

Systems Biology of GlycosylationR01HL103411 · NHLBI · STATE UNIVERSITY OF NEW YORK AT BUFFALO · PI NEELAMEGHAM, SRIRAM · 2011 to 2025
$7.1M
Extracellular Vesicle treatment and age-related neuropathology in non-human primatesR01AG068168 · NIA · BOSTON UNIVERSITY MEDICAL CAMPUS · PI MOORE, TARA L · 2020 to 2024
$3.6M
Extracellular Vesicle treatment and age-related neuropathology in non-human primatesRF1AG068168 · NIA · BOSTON UNIVERSITY MEDICAL CAMPUS · PI MOORE, TARA L · 2025 to 2025
$3.3M
Multiplex Mass Spectrometric Protein Assays for Precise Monitoring of the Pathophysiology of ObesityU01DK124020 · NIDDK · BATTELLE PACIFIC NORTHWEST LABORATORIES · PI QIAN, WEI-JUN · 2019 to 2022
$3.3M
GMPS-GMPR Axis Melanoma Progression and TherapyR01CA224434 · NCI · WAKE FOREST UNIVERSITY HEALTH SCIENCES · PI NIKIFOROV, MIKHAIL · 2018 to 2022
$2.0M
NCI NIH HHS R01 CA224434NHLBI NIH HHS R01 HL103411NIA NIH HHS R01 AG068168NIA NIH HHS RF1 AG068168NIDDK NIH HHS U01 DK124020
6 · The paper itself

Abstract

Robust, reliable quantification of large sample cohorts is often essential for meaningful clinical or pharmaceutical proteomics investigations, but it is technically challenging. When analyzing very large numbers of samples, isotope labeling approaches may suffer from substantial batch effects, and even with label-free methods, it becomes evident that low-abundance proteins are not reliably measured owing to unsufficient reproducibility for quantification. The MS1-based quantitative proteomics pipeline IonStar was designed to address these challenges. IonStar is a label-free approach that takes advantage of the high sensitivity/selectivity attainable by ultrahigh-resolution (UHR)-MS1 acquisition (e.g., 120-240k full width at half maximum at m/z = 200) which is now widely available on ultrahigh-field Orbitrap instruments. By selectively and accurately procuring quantitative features of peptides within precisely defined, very narrow m/z windows corresponding to the UHR-MS1 resolution, the method minimizes co-eluted interferences and substantially enhances signal-to-noise ratio of low-abundance species by decreasing noise level. This feature results in high sensitivity, selectivity, accuracy and precision for quantification of low-abundance proteins, as well as fewer missing data and fewer false positives. This protocol also emphasizes the importance of well-controlled, robust experimental procedures to achieve high-quality quantification across a large cohort. It includes a surfactant cocktail-aided sample preparation procedure that achieves high/reproducible protein/peptide recoveries among many samples, and a trapping nano-liquid chromatography-mass spectrometry strategy for sensitive and reproducible acquisition of UHR-MS1 peptide signal robustly across a large cohort. Data processing and quality evaluation are illustrated using an example dataset ( http://proteomecentral.proteomexchange.org ), and example results from pharmaceutical project and one clinical project (patients with acute respiratory distress syndrome) are shown. The complete IonStar pipeline takes ~1-2 weeks for a sample cohort containing ~50-100 samples.

Indexed as

ProteomicsTandem Mass SpectrometryHumansPeptidesPharmaceutical PreparationsProteomeReproducibility of ResultsPeptidesPharmaceutical PreparationsProteome

Identifiers

PMID36494494
PMCPMC10673696
OpenAlexW4311027029

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.